Q-omics provides the consensus-scored KLF6 profile across patient tissues and cancer cell-line models. KLF6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KLF6 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, KLF6 RNA expression shows 19,386 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where KLF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF6 survival associations across molecular data types. KLF6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF6 RNA expression–survival associations across cancer types. High KLF6 expression shows unfavorable associations in ACC, STAD, LGG, OV and PAAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KLF6 RNA expression.
This table summarizes KLF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF6 shows lower tumor expression in BLCA, COAD, UCEC, KICH, LUAD and LUSC. The BLCA box plot shows higher KLF6 RNA expression in normal versus tumor tissue (log2 FC = −1.477, t-test p < 0.001).
This table shows molecular features associated with KLF6 in patient tissues and cancer cell lines. In patient samples, KLF6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
